Designing a safer way to find and fight acute myeloid leukaemia cells in children
Investigating a protein found on leukaemia stem cells, the cells which cause relapse, and whether it could be a good drug target.
Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Developing ways to identify chemotherapy resistant B-cell acute lymphoblastic leukaemia cells
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.
Could a medicine called ONC-201 help treat children with T-cell acute lymphoblastic leukaemia?
Looking at whether a pre-existing drug could be an effective and safe treatment due to its ability to target cancer cells directly.
Exploring new targeted therapy options for acute myeloid leukaemia in babies
Looking for repurposed treatments that can fight leukaemia cells in very young children.
Targeting a relapse causing protein to treat childhood acute myeloid leukaemia
Investigating how a protein that causes relapse in acute myeloid leukaemia interacts with the genetic code, and whether these interactions could be prevented.
Investigating why some children get leukaemia after treatment for other cancers
Looking at the early stages of leukaemia that develops after treatment for other cancers to find out what changes occur and how to fight it.
Finding out how infant leukaemia cells interact with the immune system
Understanding how leukaemia cells enlist immune system cells to help them survive chemotherapy.
Understanding how blood cancer develops and comes back after treatment in babies
Investigating how a protein changes the way leukaemia cells behave in babies.